- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07947680
A Study on the Safety and Efficacy of Adenosylcobalamin in Patients With Declining Ovarian Function
The goal of this clinical trial is to learn if adenosylcobalamin works to treat POI and DOR. It will also learn about the safety of adenosylcobalamin. The main questions it aims to answer are:
Can adenosylcobalamin improve the clinical symptoms, signs, and hormone levels of patients with POI and DOR? What is the safety of adenosylcobalamin?
Participants will:
Take adenosylcobalamin three times a day for 3 months Visit the clinic for 5 checkups and tests
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Liru Xue
- Numéro de téléphone: CN 18727297670
- E-mail: 751400767@qq.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Premature Ovarian Insufficiency (POI): Age < 40 years old, with two consecutive basal FSH levels ≥ 25 U/L spaced 4 weeks apart, decreased anti-müllerian hormone (AMH), and clinical manifestations of oligomenorrhea or amenorrhea.
(2) Diminished ovarian reserve (DOR): Age < 40 years old, with a decrease in the number and/or quality of oocytes in the ovary, and/or accompanied by a decreased AMH level (< 1.1 ng/mL), and/or a reduced number of antral follicles (AFC) (< 6) and/or an elevated basal FSH level (> 10 U/L).
Exclusion Criteria:
- Abnormal uterine bleeding of unknown cause;
- Presence of ovarian/appendage masses ≥ 4 cm, uterine adenomyosis, uterine adenomyoma/uterine fibroids ≥ 4 cm;
- BI-RADS rating of breast ultrasound ≥ 4;
- Presence of precancerous lesions or having malignant tumors;
- Liver and kidney function indicators (ALT, AST, Urea, Cr) exceed the upper limit of normal reference values and have not returned to normal after re-examination;
- Complicated with severe primary diseases in the nervous, circulatory, respiratory, digestive, urinary or hematopoietic systems, or patients with mental disorders;
- Have received systemic hormone replacement therapy within the last 2 months;
- Are participating in other clinical trials or have participated in other clinical trials within the last 1 month;
- Have a recent fertility requirement;
- Other patients deemed unsuitable for participation in this study by the researchers.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: POI and DOR
|
Take oral adenosylcobalamin tablets, 0.5mg per dose, three times a day. Continue the treatment for 12 weeks. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
anti-müllerianhormone
Délai: Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
The serum anti-müllerianhormone(AMH) level is the primary indicator for evaluating ovarian reserve function and is used for diagnosing POI and DOR. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function. |
Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
|
sex hormones
Délai: Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
The sex hormone tests include estradiol, follicle-stimulating hormone(FSH), luteinizing hormone(LH), progesterone, testosterone and prolactin. Among them, FSH is the main indicator for diagnosing POI and DOR. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function. |
Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
|
antral follicles
Délai: Color Doppler ultrasound examination will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
The number of antral follicles refers to the total count of antral follicles observed bilaterally in the ovaries through transvaginal ultrasound examination during the early stage of follicular development. Studies have confirmed that the number of antral follicles is related to the size of the primordial follicle pool, and it can be used to assess ovarian reserve function. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function. |
Color Doppler ultrasound examination will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- TJ-IRB202611089
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .